Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 21c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 21c, Revenues Miss

 Eagle Pharmaceuticals Reports First Quarter 2021 Results

May 10, 2021 6:50 AM EDT

Q1 2021 net loss was $0.03 per basic and diluted share and adjusted non-GAAP net income was $0.24 per basic and diluted share

Anticipate vasopressin approval and launch this year; completed last required study; expect to respond to vasopressin Complete Response Letter (CRL) in full by mid-year

Expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (RTD) and Rapid Infusion (RI) formulations

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced financial results for the three... More